Crizotinib

Crizotinib is used in the treatment of non-small cell lung cancer.

How Crizotinib works?
Crizotinib is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Common side effects of Crizotinib
Nausea, Vomiting, Edema (swelling), Diarrhea, Constipation, Abdominal pain, Visual impairment, Dizziness, Taste change, Fatigue, Decreased appetite, Rash, Decreased white blood cell count (neutrophils)
How should I take Crizotinib ?
You should take Crizotinib exactly as directed by your doctor. It should be started by doctors who have experience in administering cancer medicines. Take it once a day with or without food. Do not drink grapefruit juice or eat grapefruit during your treatment with Crizotinib, as the chances of side effects may be more.
What should I do if I forget a dose?
If you miss a dose of Crizotinib by less than 12 hours, take the missed dose as soon as you remember it and then take the next dose at the scheduled time. However, if you miss a dose by more than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
In case of emergency/overdose
In case of overdose, call the poison control helpline. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call a doctor.

Contact Us







    Crizotinib (Xalkori) is a kinase inhibitor, which is a type of cancer medicine used to treat two uncommon cancers. Crizotinib is a drug that is used to treat a kind of non-small cell lung cancer (NSCLC) in persons who have a mutation in the ROS1 or ALK genes (anaplastic lymphoma kinase). In roughly 1% of persons with NSCLC, a ROS1 error occurs, while in about 5% of instances, an ALK error occurs. ROS1 and ALK mutations cause cells to proliferate out of control, resulting in cancer. Crizotinib is a drug that acts to delay or stop the progression of cancer. It accomplishes this by inhibiting ROS1 and ALK activity. It's a tyrosine kinase inhibitor for ROS1 and an ALK tyrosine kinase inhibitor for ALK. Crizotinib was the first medication approved by the US Food and Drug Administration (FDA) for patients with ROS1-positive NSCLC when it was approved in 2011. Crizotinib is also used to treat anaplastic large cell lymphoma (ALCL), an uncommon form of non-Hodgkin lymphoma (NHL) in children and young adults caused by a mutation in the ALK gene. ALK-positive ALCL cases account for over 90% of ALCL cases in young persons.

    PLEASE NOTE:

    The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.

    Enquiry Now
    Translate »

    Want Information?